The Clinical &Translational Research Center (CTRC), established in 1990 and rated Outstanding in the 2008 CCSG review, focuses on new drug development. This comprehensive 18-bed combined treatment and laboratory unit serves as the primary site for personalized, protocol-based, innovative clinical and translational research. Services provided are research infrastructure and oversight as well as 24-hour phlebotomy/lab support for pharmacologic testing. Other services include specialized processing for DNA and RNA analysis, real-time internet-based tracking of audit time-points, Ei

Public Health Relevance

The CTRC is the primary site of new drug studies for cancer and related diseases, and since 2007 it has activated 274 protocols - including many first-in-man studies. Seventeen (17) drugs approved by the FDA since 2007 were studied in Phase I or II trials in the CTRC. NIH Cooperative Group and NCI protocols represented 11% of studies activated during the grant period and MD Anderson investigator initiated studies comprised 5%. Of the total 4,057 protocol registrations, NIH peer-reviewed studies accounted for 531 (13%).

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
Rausch, Caitlin R; DiPippo, Adam J; Bose, Prithviraj et al. (2018) Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole. Clin Infect Dis 67:1610-1613
Gu, Shenda; Ngamcherdtrakul, Worapol; Reda, Moataz et al. (2018) Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment. PLoS One 13:e0198141
Fountzilas, Elena; Said, Rabih; Tsimberidou, Apostolia M (2018) Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits. Expert Opin Investig Drugs 27:155-162
Blanchard, Pierre; Davis, John W; Frank, Steven J et al. (2018) Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU Int 121:540-548
Niknam, Sharareh; Barsoumian, Hampartsoum B; Schoenhals, Jonathan E et al. (2018) Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model. Clin Cancer Res 24:5735-5743
Kamal, Mona; Ng, Sweet Ping; Eraj, Salman A et al. (2018) Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer. Oral Oncol 79:1-8
Housten, Ashley J; Pappadis, Monique R; Krishnan, Shilpa et al. (2018) Resistance to discontinuing breast cancer screening in older women: A qualitative study. Psychooncology 27:1635-1641
Hsu, Jung-Mao; Xia, Weiya; Hsu, Yi-Hsin et al. (2018) STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat Commun 9:1908
Akay, Catherine L; Albarracin, Constance; Torstenson, Tiffany et al. (2018) Factors impacting the accuracy of intra-operative evaluation of sentinel lymph nodes in breast cancer. Breast J 24:28-34
Khong, Hiep; Volmari, Annika; Sharma, Meenu et al. (2018) Peptide Vaccine Formulation Controls the Duration of Antigen Presentation and Magnitude of Tumor-Specific CD8+ T Cell Response. J Immunol 200:3464-3474

Showing the most recent 10 out of 12418 publications